Navigation Links
ASH awards grants to support critical research threatened by NIH cuts
Date:8/14/2013

(WASHINGTON, August 14, 2013) As federal funding cuts continue to jeopardize the progress of biomedical research, the American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, today announced the 12 recipients of its second round of ASH Bridge Grants. This innovative program, launched last year, supports the life-saving research of hematologists whose proposals were deemed excellent by the National Institutes of Health (NIH) but not funded due to a $1.6 billion reduction in federal funding as a direct result of sequestration.

These cuts aside, NIH's inflation-adjusted budget is 20 percent lower than it was in FY2003. According to NIH estimates, the combination of long-term flat funding and sequestration-related budget cuts will prevent the agency from funding approximately 700 competitive research project grants this year. This drastic reduction in funding will have a devastating impact on scientists who have committed their lives to careers in hematology research and will result in many talented investigators abandoning their research careers. It will also slow momentum for finding new treatments, or even cures, for some of the most deadly diseases.

"Given this harsh economic climate, instead of continuing their work searching for new treatments or cures for hematologic diseases, talented investigators who rely on NIH grants have no choice but to slow or suspend research because they no longer have the resources," said ASH President Janis L. Abkowitz, MD, of the University of Washington in Seattle. "This concerning trend ultimately threatens medical innovation and dissuades aspiring scientists from entering the field."

To help sustain crucial blood disease research during this crisis, in July 2012 ASH committed $9 million in Society funds to create this grant program, intended to provide researchers with interim support to continue their hematology research that would otherwise not be funded and ultimately to contribute to their retention in hematology investigation. ASH's one-year, $100,000 bridge grants allow basic, clinical, and translational hematology researchers whose NIH R01 series grant applications scored well but missed the funding cutoff point to continue their critical work.

The studies supported by ASH's second round of bridge grants span the breadth of hematology. Funded projects range from exploration of how computerized tomography scans may impact the use of chemotherapy for blood cancers to the study of the function of impaired gene expression in a type of congenital anemia. Other funded studies include those that seek to determine how to initiate and regulate blood clotting, improve patient outcomes after allogeneic stem cell transplantation, and better understand drug resistance to and progression of lymphoma.

"The unfortunate reality is that hematologists will require support from outside of NIH to continue moving biomedical innovation forward," said Dr. Abkowitz. "ASH was proud to provide that needed support in the form of bridge grants to nearly 30 projects in our first year. It is our hope that other medical professional societies will follow our lead in creating similar programs that will ensure that biomedical innovation does not suffer during times of financial hardship."

The ASH Bridge Grant Award Program was recently recognized as a model in the association community, earning a 2013 Summit Award from the American Society of Association Executives, the organization's highest honor, for excellence in working to create a stronger America and world.

The awards announced today represent the second of two award cycles to occur this year. The next application deadline will be November 1, 2013, and applicants will be notified of acceptance in January 2014. Beyond the Society's financial commitment that will provide for two rounds of approximately 15 bridge grants to be awarded annually through 2015, additional awards will be supplemented by support from corporate and individual contributors. Generous support from individual donors as well as Amgen, Inc.; the Atlanta Convention & Visitors Bureau; Genentech USA, Inc.; GlaxoSmithKline; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals, Inc.; and Onyx Pharmaceuticals, Inc.; enabled the Society to award several additional bridge grants as part of this second round.


'/>"/>

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Ken Jones Photography – FultonStudio on Short List for Prestigious AOP Awards
2. T.E.N. Announces Nominees for the 2013 ISE® Northeast Awards
3. All Hands on Deck for Pirate Jonny's, a "Fresh from Florida" Company Hailing From Clearwater, Receives Awards for Caribbean & Floridian BBQ Rubs, Seasonings and Sauces
4. URAC Announces Finalists for Care Coordination and Clinical Integration Best Practices Awards
5. T.E.N. Honors Top Security Executives and Projects at the ISE® West Awards
6. FHLBank Topeka Awards Economic Development Grants
7. Newsmax Magazine Wins 4 Charlie Awards
8. Major awards for innovative solutions to prevent infant/maternal deaths
9. Winners of the 39th Maddak Awards Competition for Innovative Product Design Announced at 2013 American Occupational Therapy Association Conference
10. Angel Flight West Announces The Endeavour Awards, The “Oscars of Public Benefit Aviation”
11. AMG Design Studio, Creative Design, Announces its Reception of Seven Awards in Graphic Design USA's Web Design and InHouse Competitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology: